CCCC Q1 2023 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$243M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-50.9% YoY

Gross Profit

-$25M-672.6% margin

Operating Income

-$36M-963.8% margin

Net Income

-$35M-925.2% margin

EPS (Diluted)

$-0.69

QoQ Revenue Growth

+31.7%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$34M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$396M

Total Liabilities

$134M

Stockholders' Equity

$262M

Cash & Equivalents

$49M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$8M	-50.9%
Gross Profit	-$25M	-$19M	-36.3%
Operating Income	-$36M	-$31M	-15.5%
Net Income	-$35M	-$32M	-10.0%